Research Library
SEMA / IGF-1 LR3 research
6 articles to explore, with links to 10 original sources.
About SEMA / IGF-1 LR3
This blend combines SEMA and IGF-1 LR3 in the listed Heritage amounts for laboratory research.
Explore study findings
Why two approval records describe different ingredients
Semaglutide is a modified peptide that activates the GLP-1 receptor. IGF-1 LR3 is an engineered, extended version of the insulin-like growth factor 1 protein. This entry names both molecules together.
3 sources (2023–2026)
What IGF-1 LR3 did in a lab-made skin model
Semaglutide is a peptide that activates the GLP-1 receptor. IGF-1 LR3 is an engineered version of a growth-factor protein. A 2026 tissue-engineering study used IGF-1 LR3 to investigate how cells build a supporting matrix in reconstructed skin tissue.
2 sources (2026)
Check methods and identity
Why a kidney trial measured body water as well as lean mass
Semaglutide acts at the GLP-1 receptor. IGF-1 LR3 is an altered, extended version of the growth-factor protein IGF-1. The 2026 SMART analysis studied semaglutide alone versus placebo and asked whether changes in body composition were related to kidney measurements.
2 sources (2023, 2026)
What separate Alzheimer’s studies measured for these two molecules
Semaglutide is a modified GLP-1 receptor agonist peptide. IGF-1 LR3 is an engineered growth-factor protein. Researchers have studied each in connection with Alzheimer’s disease in very different settings.
3 sources (2024, 2026)
What binding-protein measurements tell us about semaglutide
Semaglutide activates the GLP-1 receptor. IGF-1 LR3 is a modified insulin-like growth factor protein with altered binding properties. An older human study measured IGF-binding proteins during semaglutide treatment.
2 sources (1992, 2025)
Interpret the evidence
Why the bimagrumab and semaglutide trial belongs to its exact combination
Semaglutide is a peptide that activates the GLP-1 receptor. IGF-1 LR3 is an engineered growth-factor protein. A 2026 randomized trial tested semaglutide with a different add-on, the investigational antibody bimagrumab.
2 sources (1992, 2026)
